Literature DB >> 3613879

Malignancies following long-term azathioprine treatment in chronic liver disease. A report from the Copenhagen Study Group for Liver Diseases.

U Tage-Jensen, P Schlichting, H F Thomsen, G Høybye, A C Thomsen.   

Abstract

One hundred and fifty-four patients with histologically verified non-alcoholic chronic liver disease were randomized to azathioprine or prednisone treatment. After a median of 91 months observation time, the cause of death was assessed retrospectively. Autopsy was performed in 82% of 71 deaths. In the azathioprine group 33% (13/39) died from malignant neoplasia, and in the prednisone group (13%) (4/32) (p = 0.08). Considering a possible fatal outcome as a consequence of treatment, this finding urges caution in the long-term application of azathioprine at the usual dose level.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3613879     DOI: 10.1111/j.1600-0676.1987.tb00321.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  5 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Modulation of genotoxicity of azathioprine by intracellular glutathione in hepatocytes.

Authors:  K Nagafuchi; K Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.

Authors:  Truc Nguyen; Pamela M Vacek; Patrick O'Neill; Richard B Colletti; Barry A Finette
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

5.  Deflazacort for type-1 autoimmune hepatitis in a Korean girl.

Authors:  Sun Hwan Bae; Jae Seon Kim; Dong Hoon Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.